Impact of the fibrinolytic enzyme system on prognosis and survival associated with non-small cell lung carcinoma
- 1 January 2001
- journal article
- Published by Wolters Kluwer Health in Blood Coagulation & Fibrinolysis
- Vol. 12 (1) , 51-58
- https://doi.org/10.1097/00001721-200101000-00008
Abstract
Comprehensive studies of fibrinolysis in non-small cell lung carcinoma have been limited, and assignment of patients to high/low prognosis groups based on arbitrary cut-offs utilizing fibrinolytic measurements is unstandardized. This study was performed in 166 patients to examine the effects of cut-off values determined in three ways. Model 1 assigned patients to one of three equal groups (low, medium, high) based on fibrinolytic measurements made at diagnosis, Model 2 divided patients into low/high groups using median values, and Model 3 grouped according to the parameter being above/below normal range. In model 1, raised plasma fibrinogen, D-dimer and soluble fibrin were positively associated with poorer survival. In model 2, tissue plasminogen activator antigen was additionally related to poorer prognosis. Model 3 identified seven parameters as significantly related to survival, two not identified by the other models becoming significant [plasmin-antiplasmin, tissue plasminogen activator inhibitor-1 (PAI-1) antigen]. Using multivariate analysis, plasma fibrinogen level was the most uniformly significant parameter. Relative risk estimates indicated that raised plasma fibrinogen, soluble fibrin and D-dimer were associated with increased risk of death. Use of the normal/above normal cut-off is recommended to provide the maximum number of significant parameters relating to prognosis, and increased plasma D-dimer, PAI-1 antigen and fibrinogen were most closely related to survival/prognosis.Keywords
This publication has 11 references indexed in Scilit:
- Alterations to the fibrinolytic enzyme system in patients with non-small cell lung carcinomaBlood Coagulation & Fibrinolysis, 1999
- Haemostatic abnormalities in lung cancer: Prognostic implicationsEuropean Journal Of Cancer, 1997
- High plasma level of plasmin-α2-plasmin inhibitor complex is predictor of poor prognosis in patients with lung cancerClinica Chimica Acta; International Journal of Clinical Chemistry, 1996
- Plasminogen activators and their inhibitors in non-small cell lung cancer. Low content of type 2 plasminogen activator inhibitor associated with tumor disseminationCancer, 1994
- Correlation between increased granulocyte elastase release and activation of blood coagulation in patients with lung cancerCancer, 1993
- Activation of coagulation and fibrinolysis in patients with lung cancerBlood Coagulation & Fibrinolysis, 1993
- Evaluating Prethrombotic State In Lung Cancer Using Molecular MarkersChest, 1993
- Coagulation-fibrinolysis system and markers of collagen metabolism in lung cancerCancer, 1992
- Prognostic significance of blood coagulation tests in carcinoma of the lung and colonBlood Coagulation & Fibrinolysis, 1992
- Factor IXi-antithrombin (IXiAT) and thrombin-antithrombin (TAT) complexes in lung cancer patientsAnnals of Hematology, 1992